Effect of Turmeric on Diabetic Nephropathy

This study has been completed.
Sponsor:
Collaborator:
Shiraz University of Medical Sciences
Information provided by:
Shaheed Faghihi Hospital
ClinicalTrials.gov Identifier:
NCT01015937
First received: November 16, 2009
Last updated: November 17, 2009
Last verified: November 2009

November 16, 2009
November 17, 2009
March 2008
June 2009   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01015937 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effect of Turmeric on Diabetic Nephropathy
Not Provided

The purpose of this study is to investigate whether turmeric is effective in improvement of diabetic nephropathy and in decrease in the amount of proteinuria and cytokine levels.

Diabetic nephropathy is leading cause of ESRF that many therapy recommended for it. In this study, we investigate effect of turmeric on diabetic nephropathy, thus we selected diabetic nephropathy patients and divided them into 2 groups. One group received turmeric + ACE inhibitor + Angiotensin II receptor blocker (ARB) and the second group received only ACE inhibitor + ARB.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Diabetic Nephropathy
  • Proteinuria
  • Drug: Turmeric extract
    turmeric 500 mg TID for 45 days
    Other Name: turmeric
  • Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
    maximum dosage as patient tolerated for 45 days
    Other Names:
    • enalapril
    • losartan
  • Active Comparator: Turmeric

    diabetic nephropathy patient

    more than 300 mg/proteinuria

    Intervention: Drug: Turmeric extract
  • Active Comparator: ACE inhibitor + ATI blocker

    diabetic nephropathy

    more than 300 mg/day proteinuria

    Interventions:
    • Drug: Turmeric extract
    • Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
August 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • diabetic nephropathy
  • more than 300 mg proteinuria/day
  • age more than 18 years old

Exclusion Criteria:

  • DM type 1
Both
18 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
NCT01015937
3997
Yes
Office of Vice Chancellor for research in Shiraz UMS, Shiraz University of Medical Science
Shaheed Faghihi Hospital
Shiraz University of Medical Sciences
Principal Investigator: maryam pakfetrat, assistant professor Shiraz nephro-urology research center
Shaheed Faghihi Hospital
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP